Fulacimstat (BAY1142524)
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Clinical Trial, Phase I
Conditions
Clinical Trial, Phase I
Trial Timeline
Feb 12, 2018 → Mar 19, 2019
NCT ID
NCT03402438About Fulacimstat (BAY1142524)
Fulacimstat (BAY1142524) is a phase 1 stage product being developed by Bayer for Clinical Trial, Phase I. The current trial status is completed. This product is registered under clinical trial identifier NCT03402438. Target conditions include Clinical Trial, Phase I.
What happened to similar drugs?
1 of 4 similar drugs in Clinical Trial, Phase I were approved
Approved (1) Terminated (1) Active (3)
Hype Score Breakdown
Clinical
6
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03402438 | Phase 1 | Completed |
Competing Products
20 competing products in Clinical Trial, Phase I